These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9826227

  • 1. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
    Léger G, Gjedde A, Kuwabara H, Guttman M, Cumming P.
    Synapse; 1998 Dec; 30(4):351-61. PubMed ID: 9826227
    [Abstract] [Full Text] [Related]

  • 2. Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition.
    Psylla M, Günther I, Antonini A, Vontobel P, Reist HW, Zollinger A, Leenders KL.
    Brain Res; 1997 Aug 29; 767(1):45-54. PubMed ID: 9365014
    [Abstract] [Full Text] [Related]

  • 3. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
    Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Margouleff C, Eidelberg D.
    J Cereb Blood Flow Metab; 1996 Sep 29; 16(5):854-63. PubMed ID: 8784230
    [Abstract] [Full Text] [Related]

  • 4. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK.
    Synapse; 1997 Dec 29; 27(4):336-46. PubMed ID: 9372556
    [Abstract] [Full Text] [Related]

  • 5. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
    Cumming P, Gjedde A.
    Synapse; 1998 May 29; 29(1):37-61. PubMed ID: 9552174
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
    Doudet DJ, Chan GL, Holden JE, Pate BD, Morrison KS, Calne DB, Ruth TJ.
    Eur J Pharmacol; 1997 Sep 03; 334(1):31-8. PubMed ID: 9346324
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
    Ishiwata K, Shinoda M, Ishii S, Nozaki T, Senda M.
    Nucl Med Biol; 1996 Apr 03; 23(3):295-301. PubMed ID: 8782240
    [Abstract] [Full Text] [Related]

  • 13. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
    Rousset OG, Deep P, Kuwabara H, Evans AC, Gjedde AH, Cumming P.
    Synapse; 2000 Aug 03; 37(2):81-9. PubMed ID: 10881028
    [Abstract] [Full Text] [Related]

  • 14. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T, Prikhojan A, Yahr MD.
    J Neural Transm (Vienna); 1997 Aug 03; 104(1):77-87. PubMed ID: 9085195
    [Abstract] [Full Text] [Related]

  • 15. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S, Gordin A, Männistö PT.
    Gen Pharmacol; 1994 Sep 03; 25(5):813-24. PubMed ID: 7835624
    [Abstract] [Full Text] [Related]

  • 16. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
    Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A.
    Mov Disord; 1993 Jul 03; 8(3):298-304. PubMed ID: 8341294
    [Abstract] [Full Text] [Related]

  • 17. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.
    Holden JE, Doudet D, Endres CJ, Chan GL, Morrison KS, Vingerhoets FJ, Snow BJ, Pate BD, Sossi V, Buckley KR, Ruth TJ.
    J Nucl Med; 1997 Oct 03; 38(10):1568-74. PubMed ID: 9379194
    [Abstract] [Full Text] [Related]

  • 18. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S, Gordin A, Järvinen M, Wikberg T, Schultz E, Nissinen E, Pentikäinen PJ, Rita H.
    Clin Neuropharmacol; 1990 Oct 03; 13(5):436-47. PubMed ID: 2272023
    [Abstract] [Full Text] [Related]

  • 19. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
    Laihinen A, Rinne JO, Rinne UK, Haaparanta M, Ruotsalainen U, Bergman J, Solin O.
    Neurology; 1992 Jan 03; 42(1):199-203. PubMed ID: 1734304
    [Abstract] [Full Text] [Related]

  • 20. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
    Ruottinen HM, Niinivirta M, Bergman J, Oikonen V, Solin O, Eskola O, Eronen E, Sonninen P, Rinne UK.
    Synapse; 2001 Apr 03; 40(1):19-26. PubMed ID: 11170218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.